1066vip威尼斯 - Apple App Store

Held at Guangzhou’s Baiyun International Convention Centre (April 10th – 13th 2019), the 21st Southern China Cardiovascular Disease Conference (SCC) brought in renowned cardiovascular experts to discuss the latest progress in cardiovascular research, as well as provide in-depth discussions on the future of the cardiovascular disease/treatment in China. Sponsored by the Guangdong Medical Association and the Guangdong Provincial Medical Association, the SCC conference aims to promote clinical care of cardiovascular related diseases in China.

ReLIA Biotech has and is always committed to the research and development of rapid diagnostic devices specialized in cardiovascular diseases. It has launched a variety of cardiovascular disease detection reagents to meet the needs of cardiovascular diagnosis and care in China. High-sensitive cardiac troponin (hs-cTnl) in particular, has been recently utilized as a bedside biomarker reagent. With a high sensitivity and specificity, hs-cTnl not only minimizes misinterpretations in “grey zone” results but can also allow for earlier detection of myocardial infarction. ReLIA Biotech doesn’t just focus on cardiovascular diagnostics, but also renal function and infection tests as well.

In this particular conference, ReLIA Biotech unveiled the TZ-301 dry fluorescence immunoassay analyzer and the new model TZ-320 dry immunofluorescence detector as well as the use of hs-cTnl and NT-proBNP biomarkers in test reagents.